Literature DB >> 8697164

Long-term follow up of patients with dilated heart muscle disease treated with human leucocytic interferon alpha or thymic hormones initial results.

M Mirić1, J Vasiljević, M Bojić, Z Popović, N Keserović, M Pesić.   

Abstract

OBJECTIVE: To determine whether giving interferon-alpha or thymomodulin in addition to conventional treatment improves cardiac function in patients with idiopathic myocarditis and idiopathic dilated cardiomyopathy.
DESIGN: Single-centre, randomised, open label, parallel group comparison of conventional treatment plus interferon-alpha, conventional treatment plus thymomodulin, and conventional treatment alone. PATIENTS: 38 patients aged 19-54 years (23 men) with biopsy-proven myocarditis or dilated cardiomyopathy. 12 were treated with conventional treatment alone, 13 were treated with interferon-alpha and conventional treatment, and 13 with thymomodulin and conventional treatment.
SETTING: Tertiary cardiac referral centre. MAIN OUTCOME MEASURES: Clinical evaluation, echocardiography, and Holter monitoring at baseline, 6 months, and 1 and 2 years. Radionuclide ventriculography at rest and during exercise after 2 years. Endomyocardial biopsy at baseline and after a year if the initial diagnosis was myocarditis.
RESULTS: Left ventricular ejection fraction was improved in 21 (81%) of 26 patients after interferon-alpha or thymomodulin administration and in 8 (66%) of 12 conventionally treated patients (P < 0.05) at 2 year follow up. The maximum exercise time was significantly longer at 2-year follow up in patients treated with immunomodulators (mean (SEM) 5.1 (0.6) minutes for interferon-alpha and 5.0 (0.4) minutes for thymomodulin) than in conventionally treated patients (3.3 (0.4) minutes). Left ventricular ejection fraction during exercise (assessed by radionuclide ventriculography) improved in 9 of 12 patients treated with interferon-alpha, 10 of 12 patients treated with thymomodulin, and 3 of 9 conventionally treated patients at 2 year follow up. The electrocardiogram was normal in 21 (88%) of 24 patients after interferon-alpha or thymomodulin treatment and 2 (22%) of 9 conventionally treated patients. At 2 year follow up, 19 (73%) of 26 patients treated with immunomodulators and 4 (25%) of 12 conventionally treated patients had improved their functional class.
CONCLUSIONS: The results suggest that treatment of idiopathic myocarditis and/or idiopathic dilated cardiomyopathy with interferon-alpha or thymomodulin induces an earlier and significantly superior clinical improvement than conventional treatment alone.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8697164      PMCID: PMC484384          DOI: 10.1136/hrt.75.6.596

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  18 in total

Review 1.  Membrane and cytoplasmic changes in virus-infected cells induced by interactions of antiviral antibody with surface viral antigen.

Authors:  M B Oldstone; R S Fujinami; P W Lampert
Journal:  Prog Med Virol       Date:  1980

2.  Sendai virus infection in the brains of mice: distribution of viral antigens studied with monoclonal antibodies.

Authors:  K Kristensson; C Orvell; J Leestma; E Norrby
Journal:  J Infect Dis       Date:  1983-02       Impact factor: 5.226

3.  Restricted expression of viral glycoprotein in cells of persistently infected mice.

Authors:  M B Oldstone; M J Buchmeier
Journal:  Nature       Date:  1982-11-25       Impact factor: 49.962

4.  A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators.

Authors:  J W Mason; J B O'Connell; A Herskowitz; N R Rose; B M McManus; M E Billingham; T E Moon
Journal:  N Engl J Med       Date:  1995-08-03       Impact factor: 91.245

5.  Cytotoxicity against the K562 erythroleukemia cell line by human natural killer (NK) cells which do not bear free Fc receptors for IgG.

Authors:  H D Kay; R Fagnani; G D Bonnard
Journal:  Int J Cancer       Date:  1979-08       Impact factor: 7.396

6.  Cytotoxic activity and interferon production by lymphocytes from patients with multiple sclerosis.

Authors:  D Santoli; W Hall; L Kastrukoff; R P Lisak; B Perussia; G Trinchieri; H Koprowski
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

7.  Diagnostic relevance of humoral and cell-mediated immune reactions in patients with acute viral myocarditis.

Authors:  B Maisch; R Trostel-Soeder; E Stechemesser; P A Berg; K Kochsiek
Journal:  Clin Exp Immunol       Date:  1982-06       Impact factor: 4.330

8.  Circulating immune complexes in cystic fibrosis and their correlation to clinical parameters.

Authors:  M L Disis; T L McDonald; J L Colombo; R H Kobayashi; C R Angle; S Murray
Journal:  Pediatr Res       Date:  1986-05       Impact factor: 3.756

9.  Detection of Coxsackie-B-virus-specific RNA sequences in myocardial biopsy samples from patients with myocarditis and dilated cardiomyopathy.

Authors:  N E Bowles; P J Richardson; E G Olsen; L C Archard
Journal:  Lancet       Date:  1986-05-17       Impact factor: 79.321

10.  The effects of long-term administration of recombinant alpha-2 interferon on lymphocyte subsets, proliferation, and suppressor cell function in multiple sclerosis.

Authors:  R L Hirsch; K P Johnson
Journal:  J Interferon Res       Date:  1986-04
View more
  13 in total

1.  Interferon regulatory factor 3 is required for viral induction of beta interferon in primary cardiac myocyte cultures.

Authors:  D L Noah; M A Blum; B Sherry
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

2.  A single-amino-acid polymorphism in reovirus protein μ2 determines repression of interferon signaling and modulates myocarditis.

Authors:  Susan C Irvin; Jennifer Zurney; Laura S Ooms; James D Chappell; Terence S Dermody; Barbara Sherry
Journal:  J Virol       Date:  2011-12-07       Impact factor: 5.103

3.  Basal and reovirus-induced beta interferon (IFN-beta) and IFN-beta-stimulated gene expression are cell type specific in the cardiac protective response.

Authors:  Michael J Stewart; Kathleen Smoak; Mary Ann Blum; Barbara Sherry
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

Review 4.  Viral heart disease: molecular diagnosis, clinical prognosis, and treatment strategies.

Authors:  Matthias Pauschinger; Kumaran Chandrasekharan; Michel Noutsias; Uwe Kühl; Lothar Peter Schwimmbeck; Heinz-Peter Schultheiss
Journal:  Med Microbiol Immunol       Date:  2004-01-14       Impact factor: 3.402

Review 5.  An approach to the treatment of pediatric myocarditis.

Authors:  Daniel Levi; Juan Alejos
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

6.  IFN-alpha expression and antiviral effects are subtype and cell type specific in the cardiac response to viral infection.

Authors:  Lianna Li; Barbara Sherry
Journal:  Virology       Date:  2009-11-06       Impact factor: 3.616

7.  Basal expression levels of IFNAR and Jak-STAT components are determinants of cell-type-specific differences in cardiac antiviral responses.

Authors:  Jennifer Zurney; Kristina E Howard; Barbara Sherry
Journal:  J Virol       Date:  2007-10-17       Impact factor: 5.103

Review 8.  Innovative drug treatments for viral and autoimmune myocarditis.

Authors:  S Anandasabapathy; W H Frishman
Journal:  J Clin Pharmacol       Date:  1998-04       Impact factor: 3.126

9.  Diagnosis and management of viral myocarditis.

Authors:  William H Frishman; Joshua Zeidner; Nauman Naseer
Journal:  Curr Treat Options Cardiovasc Med       Date:  2007-12

10.  Immunomodulatory treatment for lymphocytic myocarditis-a systematic review and meta-analysis.

Authors:  Max-Paul Winter; Patrick Sulzgruber; Lorenz Koller; Philipp Bartko; Georg Goliasch; Alexander Niessner
Journal:  Heart Fail Rev       Date:  2018-07       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.